Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin City, China.
Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin City, China.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820973276. doi: 10.1177/1533033820973276.
MicroRNAs (miRNAs) have been found to play important roles in the development of non-small cell lung carcinoma (NSCLC). The aim of this study was to analyze the expression and clinical value of serum miR-185 in NSCLC.
Serum miR-185 levels were detected in 146 NSCLC patients, 50 patients with carcinoma in situ, 25 patients with non-malignant lung diseases (NMLD), and 80 healthy controls using quantitative reverse transcription PCR. The correlation between serum miR-185 level and clinical status of NSCLC was explored.
The results revealed that serum miR-185 expression was progressively decreased in healthy controls, patients with NMLD, patients with carcinoma in situ and NSCLC patients. In addition, compared to carcinoembryonic antigen (CEA), serum miR-185 demonstrated better diagnostic accuracy for discriminating patients with carcinoma from healthy controls, NSCLC patients from healthy controls and NSCLC patients from patients with carcinoma in situ. In addition, serum miR-185 levels were significantly elevated in post-treated samples compared to the pre-treated samples. Moreover, reduced serum miR-185 was closely associated with unfavorable clinicopathological parameters and worse survival. Univariate and multivariate cox regression analysis confirmed that serum miR-185 was an independent prognostic indicator for NSCLC.
Collectively, our findings have demonstrated that serum miR-185 might serve as a promising and robust biomarker for the early detection and prognosis prediction of NSCLC.
已发现 microRNAs（miRNAs）在非小细胞肺癌（NSCLC）的发展中发挥重要作用。本研究旨在分析血清 miR-185 在 NSCLC 中的表达及其临床价值。
采用定量逆转录 PCR 检测 146 例 NSCLC 患者、50 例原位癌患者、25 例非恶性肺部疾病（NMLD）患者和 80 例健康对照者的血清 miR-185 水平，探讨血清 miR-185 水平与 NSCLC 临床状况的相关性。
结果显示，血清 miR-185 表达水平在健康对照组、NMLD 患者、原位癌患者和 NSCLC 患者中逐渐降低。与癌胚抗原（CEA）相比，血清 miR-185 鉴别健康对照者、健康对照者与 NSCLC 患者、原位癌患者与 NSCLC 患者的诊断准确性更好。此外，与治疗前样本相比，治疗后样本中血清 miR-185 水平显著升高。而且，血清 miR-185 水平降低与不良临床病理参数和生存状况较差密切相关。单因素和多因素 Cox 回归分析证实，血清 miR-185 是 NSCLC 的独立预后指标。
综上，本研究结果表明，血清 miR-185 可能是一种有前途且稳健的 NSCLC 早期检测和预后预测的生物标志物。
